Henry Schein, Inc. (NASDAQ:HSIC) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Henry Schein, Inc. (NASDAQ:HSIC) have been given a consensus recommendation of “Hold” by the fourteen research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $76.6923.

Several research analysts have issued reports on the company. Wall Street Zen raised Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Barrington Research set a $79.00 target price on Henry Schein and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Barclays started coverage on Henry Schein in a report on Monday, December 8th. They set an “overweight” rating and a $86.00 target price for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Henry Schein from $76.00 to $78.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th.

Henry Schein Price Performance

Shares of NASDAQ HSIC opened at $77.73 on Wednesday. Henry Schein has a twelve month low of $60.56 and a twelve month high of $82.49. The company has a current ratio of 1.40, a quick ratio of 0.79 and a debt-to-equity ratio of 0.54. The firm has a 50-day moving average of $75.51 and a two-hundred day moving average of $70.56. The company has a market capitalization of $9.15 billion, a price-to-earnings ratio of 24.60, a PEG ratio of 2.38 and a beta of 0.88.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, November 4th. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.11. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. The business had revenue of $3.34 billion for the quarter, compared to the consensus estimate of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. As a group, analysts expect that Henry Schein will post 4.74 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Henry Schein

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HSIC. MAI Capital Management raised its stake in shares of Henry Schein by 7.5% in the third quarter. MAI Capital Management now owns 2,061 shares of the company’s stock valued at $137,000 after buying an additional 144 shares during the period. Vanguard Personalized Indexing Management LLC increased its holdings in Henry Schein by 3.5% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 4,669 shares of the company’s stock worth $341,000 after acquiring an additional 157 shares during the last quarter. Equitable Trust Co. raised its stake in Henry Schein by 3.1% in the 2nd quarter. Equitable Trust Co. now owns 5,317 shares of the company’s stock valued at $388,000 after acquiring an additional 158 shares during the period. CW Advisors LLC lifted its holdings in Henry Schein by 2.8% during the second quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock valued at $432,000 after purchasing an additional 163 shares during the last quarter. Finally, TD Asset Management Inc boosted its position in Henry Schein by 0.8% during the second quarter. TD Asset Management Inc now owns 22,016 shares of the company’s stock worth $1,608,000 after purchasing an additional 164 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.